Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : says working with regulators on best approach to lower dose regimen

11/27/2020 | 04:08am EST

LONDON (Reuters) - AstraZeneca is working with regulators to investigate a lower dosage of its vaccine that performed better than a full dosage, a spokesman for the company said, after its chief executive was quoted as saying an additional global trial was likely.

Asked about the Bloomberg report on the additional trial, a spokesman for AstraZeneca said: "As we communicated earlier this week, there is strong merit in continuing to further investigate the half-dose/full dose regimen."

"We are further evaluating the data and will work with regulators on the best approach for further evaluation. This would add to data from existing trials which are currently being prepared for regulatory submission," he said.

(Reporting by Alistair Smout, Editing by Rosalba O'Brien)


© Reuters 2020
All news about ASTRAZENECA PLC
04:31aSterling eases off recent highs as investors temper vaccine optimism
RE
04:24aEUROPE : European shares hit near 1-month low after Wall Street sell-off
RE
04:20aGlobal stocks soured by Wall Street sell-off and 'vaccine nationalism'
RE
03:25aASTRAZENECA : launches Africa PUMUA Initiative to redefine asthma care in Africa
AQ
03:20aOil falls on COVID-19-induced demand worries, stronger dollar
RE
03:09aASTRAZENECA : launches Africa PUMUA Initiative to redefine asthma care in Africa..
AQ
02:01aCELLINK : announces third year extension of collaboration with a global biopharm..
AQ
01/27ASTRAZENECA : COVID-19 Vaccine Production Unaffected After Suspicious Package 'M..
MT
01/27ASTRAZENECA : EU Asks AstraZeneca to Source COVID-19 Doses from British Plants
MT
01/27ASTRAZENECA : COVID-19 Vaccine Wins Emergency Use Approval In Philippines
MT
More news
Financials (USD)
Sales 2020 26 378 M - -
Net income 2020 2 951 M - -
Net Debt 2020 13 468 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 140 B -
EV / Sales 2020 5,80x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 127,03 $
Last Close Price 106,32 $
Spread / Highest target 47,8%
Spread / Average Target 19,5%
Spread / Lowest Target -15,1%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.21%139 938
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
PFIZER INC.-1.55%201 436
MERCK & CO., INC.-5.78%194 990